LENZ Total Current Assets from 2010 to 2024

LENZ Stock   27.99  1.67  6.34%   
LENZ Therapeutics Total Current Assets yearly trend continues to be fairly stable with very little volatility. Total Current Assets are likely to outpace its year average in 2024. Total Current Assets is the total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle. View All Fundamentals
 
Total Current Assets  
First Reported
2010-12-31
Previous Quarter
188 M
Current Value
190.6 M
Quarterly Volatility
125.1 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check LENZ Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among LENZ Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.6 M, Interest Expense of 48 K or Other Operating Expenses of 55.6 M, as well as many indicators such as Price To Sales Ratio of 19.7, Dividend Yield of 0.0 or PTB Ratio of 0.58. LENZ financial statements analysis is a perfect complement when working with LENZ Therapeutics Valuation or Volatility modules.
  
Check out the analysis of LENZ Therapeutics Correlation against competitors.
For more information on how to buy LENZ Stock please use our How to Invest in LENZ Therapeutics guide.

Latest LENZ Therapeutics' Total Current Assets Growth Pattern

Below is the plot of the Total Current Assets of LENZ Therapeutics over the last few years. It is the total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle. LENZ Therapeutics' Total Current Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in LENZ Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Total Current Assets10 Years Trend
Slightly volatile
   Total Current Assets   
       Timeline  

LENZ Total Current Assets Regression Statistics

Arithmetic Mean70,457,055
Geometric Mean175,976
Coefficient Of Variation177.60
Mean Deviation100,515,280
Median6,000
Standard Deviation125,128,442
Sample Variance15657.1T
Range381.7M
R-Value0.69
Mean Square Error8764.1T
R-Squared0.48
Significance0
Slope19,389,463
Total Sum of Squares219199.8T

LENZ Total Current Assets History

2024190.6 M
2023188 M
2022275.4 M
2021381.7 M
202021.1 M

About LENZ Therapeutics Financial Statements

LENZ Therapeutics investors use historical fundamental indicators, such as LENZ Therapeutics' Total Current Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in LENZ Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Current Assets188 M190.6 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for LENZ Stock Analysis

When running LENZ Therapeutics' price analysis, check to measure LENZ Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LENZ Therapeutics is operating at the current time. Most of LENZ Therapeutics' value examination focuses on studying past and present price action to predict the probability of LENZ Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LENZ Therapeutics' price. Additionally, you may evaluate how the addition of LENZ Therapeutics to your portfolios can decrease your overall portfolio volatility.